| abstract |
Disclosed is the use of racemic, (R)-enriched or (S)-enriched N-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the reduction of gastrointestinal motility in a subject suffering from an abnormal increase in gastrointestinal motility, wherein said abnormal increase in gastrointestinal motility is caused by at least one condition chosen from inflammatory bowel disease, ulcerative colitis, granulomatous enteritis, infectious diseases of the small or large intestine, pyloric spasm, abdominal cramps, a functional bowel disorder, mild dysenteries, diverticulitis, acute enterocolitis, neurogenic bowel disorders, splenic flexure syndrome, neurogenic colon, spastic colitis, or is a symptom of any of the foregoing conditions. |